Percentage Volume Oscillator PVO Definition & Meaning | Technical Indicator | CSIMarket
CSI Market
Sign In | Register

Glossary

Percentage Volume Oscillator PVO

Technical Indicator

The Percentage Volume Oscillator (PVO) is a technical indicator used in chart analysis to measure the momentum and volume of a security instrument over a specified period. It is calculated by taking the difference between two volume-weighted moving averages and then dividing that difference by the average of the two moving averages.

The PVO helps traders and analysts identify potential trends and changes in trend momentum in a security instrument that may not be evident in price movements alone. The PVO is typically used in conjunction with other technical indicators such as moving averages, trend lines, and chart patterns to provide a more complete picture of price and volume trend movements.

Traders can use the PVO in a number of ways, including identifying divergences between the indicator and the price of the security instrument, identifying overbought and oversold conditions, and using it as a signal for entry and exit points.

The formula for PVO is as follows:

PVO = [(Volume Weighted Moving Average short term - Volume Weighted Moving Average long term) / Volume Weighted Moving Average long term] x 100

Where:

Volume Weighted Moving Average short term = the short term moving average of volume
Volume Weighted Moving Average long term = the long term moving average of volume




More Glossary Terms Beginning with P
  • Paediatric Exclusivity
    means, in the US, a six-month period of exclusivity to market a drug which is awarded by the FDA in return for certain paediatric clinical studies using that drug. This six-month period runs from the date of relevant patent expiry.
    Health Care Term Letter: P
  • Paid Development Method
    An actuarial method to estimate ultimate losses for a given cohort of claims such as an accident year/product line component. If the paid-to-date losses are then subtracted from the estimated ultimate losses, the result is an indication of the unpaid losses. The basic premise of the method is that cumulative paid losses for a given cohort of claims will grow in a stable, predictable pattern from y
    Insurance Term Letter: P
  • Panelboards
    Oriented strand board, particleboard, medium density fibreboard and plywood. Operating Statistics
    Manufacturing Term Letter: P
  • Partial Remission PR
    A decrease in the size of a tumor, or in the extent of cancer in the body, in response to treatment.
    Health Care Term Letter: P
  • Particleboard
    A panelboard produced by chemically bonding clean sawdust, small wood particles and recycled wood fibre under heat and pressure. Forestry & Wood Products Industry Operating Statistics
    Manufacturing Term Letter: P
  • Particulate Matter
    Total suspended particulate. A measure of the solid particles (wood, process dust and smoke) found in air emissions.
    Manufacturing Term Letter: P
  • Particulates
    Tiny particles of a substance.
    Manufacturing Term Letter: P
  • Passenger Load Factor
    Represents the total number of seats sold as a percentage of total seat capacity on all sectors flown. Airline Industry
    Transportation Term Letter: P
  • Passenger Mile Yield
    The amount of passenger revenue earned per revenue passenger mile during a reporting period Airline Industry
    Transportation Term Letter: P
  • Passenger revenue yield per Mile Average Yield per RPM
    Represents the average scheduled passenger fare revenue for each revenue passenger mile (RPM), or each mile a scheduled revenue passenger is flown. Airline Industry
    Transportation Term Letter: P
  • Passive Immunotherapy
    Immunologically active material transferred into the patient as a passive recipient. Monoclonal antibodies are considered Passive Immunotherapy since antibodies are generated outside the body and given to the patient
    Health Care Term Letter: P
  • Patent Term Extension
    means an extension of up to five years in the term of a US patent relating to a drug which compensates for delays in marketing resulting from the need to obtain FDA approval.
    Health Care Term Letter: P